Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.47 |
| ▸ | NPC1 | O15118 | 2/20 | 0.47 |
| ▸ | RAB9A | P51151 | 2/20 | 0.47 |
| ▸ | HTT | P42858 | 1/20 | 0.47 |
| ▸ | KDM1A | O60341 | 2/20 | 0.46 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.46 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.46 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.46 |
| ▸ | MEN1 | O00255 | 1/20 | 0.46 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.46 |
| ▸ | NAMPT | P43490 | 1/20 | 0.44 |
| ▸ | CTSL | P07711 | 1/20 | 0.43 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.43 |
| ▸ | OPRK1 | P41145 | 2/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.43 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.42 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.42 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.42 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.42 |
| ▸ | GRIN2B | Q13224 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29364160 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL18860228 | 1.00 | SMN1; SMN2 (0.47) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL6947042 | 0.94 | PDE4B (0.44) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL9994136 | 0.92 | NAMPT (0.48) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL28452865 | 0.89 | KDM1A (0.44) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL18330207 | 0.89 | KDM1A (0.44) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL8323492 | 0.88 | PDE4B (0.45) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL8323496 | 0.88 | PDE4B (0.45) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL26627091 | 0.87 | PDE4B (0.46) | SMN1; SMN2NPC1RAB9AHTTKDM1A | |
| SCHEMBL8328356 | 0.85 | ENPP2 (0.52) | SMN1; SMN2NPC1RAB9AHTTKDM1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3340988-B1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI INC (US) | 2025-04-09 | — | — | EP | disclosed |
| CN-108289886-B | Ion channel inhibiting compounds, pharmaceutical formulations and uses | 安华赛公司 | 2022-01-28 | — | — | CN | disclosed |
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | AFASCI, INC. (US) | 2020-02-18 | — | — | US | disclosed |
| EP-3292110-B1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME (NL) | 2019-08-21 | — | — | EP | disclosed |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | AFASCI, INC. (US) | 2018-11-01 | — | — | US | disclosed |
| EP-3340988-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | Afasci, Inc. (US) | 2018-07-04 | — | — | EP | disclosed |
| EP-3292110-A1 | N-PIPERIDIN-4-YL DERIVATIVES | Merck Sharp & Dohme B.V. (NL) | 2018-03-14 | — | — | EP | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| WO-2017083867-A1 | ION CHANNEL INHIBITORY COMPOUNDS, PHARMACEUTICAL FORMULATIONS AND USES | AFASCI, INC. (US) | 2017-05-18 | — | — | WO | disclosed |
| US-8993757-B2 | N-piperidin-4-yl derivatives | MERCK SHARP & DOHME B.V. (NL) | 2015-03-31 | — | — | US | disclosed |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MERCK SHARP & DOHME B.V. (NL) | 2014-11-06 | — | — | US | disclosed |
| WO-2013041457-A1 | N-PIPERIDIN-4-YL DERIVATIVES | MSD OSS B.V. (NL) | 2013-03-28 | — | — | WO | disclosed |
| EP-0641339-B1 | AZASPIRO QUINOLONE ANTIBACTERIAL AGENTS | PFIZER (US) | 1999-09-15 | — | — | EP | disclosed |
| US-5407943-A | Azaspiro quinolone antibacterial agents | PFIZER INC. (US) | 1995-04-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10562857-B2 | Ion channel inhibitory compounds, pharmaceutical formulations, and uses | CACNA1I, CACNA1G, CACNA1H | SMN1; SMN2 513/4885NPC1 1069/4885RAB9A 1404/4885 |
| US-20140329822-A1 | N-PIPERIDIN-4-YL DERIVATIVES | PGR, CYP19A1, BRCA1 | SMN1; SMN2 2841/4885NPC1 2207/4885RAB9A 1611/4885 |
| US-20180312471-A1 | Ion Channel Inhibitory Compounds, Pharmaceutical Formulations, and Uses | CACNA1I, CACNA1G, CACNA1H | SMN1; SMN2 513/4885NPC1 1069/4885RAB9A 1404/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.